Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Insulin glulisine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Apidra is an antidiabetic agent, used to reduce high blood sugar in patients with diabetes mellitus; it may be given to adults, adolescents and children, 6 years of age and older. Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. It is made by biotechnology. It has a rapid onset within 10-20 minutes and a short duration, about 4 hours.
e Apidra Do not use Apidra
There is insufficient clinical information on the use of Apidra in children younger than the age of 6 years. Skin changes at the injection site The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (see How to use Apidra). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. Travel Before travelling consult your doctor. You may need to talk about
(used to treat certain heart conditions or high blood pressure),
958664 028 1 26.03.2026 GS09 <MAT>958664
Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:
Important information about some of the ingredients of Apidra This medicine contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially 'sodium-free'. Apidra contains metacresol Apidra contains metacresol, which may cause allergic reactions.
Apidra Dose Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will determine how much Apidra you will need. Apidra is a short-acting insulin. Your doctor may tell you to use it in combination with an intermediate, long acting insulin, a basal insulin or with tablets used to treat high blood sugar levels. If you switch from another insulin to insulin glulisine, your dosage may have to be adjusted by your doctor. Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information. Method of administration Apidra is injected under the skin (subcutaneously). Your doctor will show you in which area of the skin you should inject Apidra. Apidra can be injected in the abdominal wall, the thigh or upper arm or by continuous infusion in the abdominal wall. The effect will be slightly quicker if the insulin is injected into your abdomen. As for all insulins, injection sites and infusion sites within an injection area (abdomen, thigh or upper arm) must be rotated from one injection to the next.
Apidra with alcohol Your blood sugar levels may either rise or fall if you drink alcohol.
Frequency of administration Apidra should be taken shortly (0-15 minutes) before or soon after meals.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Inform your doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby. There are no or limited data on the use of Apidra in pregnant women. If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.
Instructions for proper use How to handle SoloStar SoloStar is a pre‐filled disposable pen containing insulin glulisine. Apidra in a pre‐filled pen is only suitable for injecting just under the skin. Speak to your doctor if you need to inject your insulin by another method.
Driving and using machines Your ability to concentrate or react may be reduced if:
Legende / Legend SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date: DMC-Inhalt / DMC content:
Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines). You should contact your doctor for advice on driving if:
296 x 628 mm 9 Pt 10 Pt 1/2
Read carefully the "SoloStar Instructions for use" included in this package leaflet. You must use the pen as described in these Instructions for use. To prevent the possible transmission of disease, each pen must be used by one patient only. Before use always attach a new needle, and perform a safety test. Only use needles that are compatible for use with SoloStar (see "SoloStar Instructions for use"). Look at the cartridge sealed in the disposable pen injector before you use it. Only use it if the solution is clear, colourless and has no visible particles in it.
Druckbare Farben / Printing colours
Technische Information / Technical information
Pantone Black C
Kontur / Outline
Do not shake or mix it before use. Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. If you think you may have a problem with SoloStar, please consult your Health Care Professional. If you use more Apidra than you should
<MAT>958664
Hyperglycaemia (high blood sugar) means that there is too much sugar in the blood. The frequency of hyperglycaemia cannot be estimated. If your blood sugar level is too high, this tells you that you may need more insulin than you have injected. This can be serious if your blood glucose level becomes very high. For more information on signs and symptoms of hyperglycaemia refer to the box at the end of this leaflet. Other side effects Tell your doctor, pharmacist or nurse if you notice any of the following side effects:
In-use pens Pre-filled pens in use (or carried as a spare) may be stored for a maximum of 4 weeks below 25 °C and away from direct heat or direct light. The pen in use must not be stored in a refrigerator. Do not use it after this time period. Do not use this medicine if it does not appear clear and colourless. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
not listed in this leaflet.
Manufacturer Sanofi-Aventis Deutschland GmbH Industriepark Höchst, D-65926 Frankfurt Germany
You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist.
By reporting side effects you can help provide more information on the safety of this medicine.
This leaflet was last revised in April 2026
Apidra Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date, which is stated on the carton and on the label of the pen after "EXP". The expiry date refers to the last day of that month. Not in-use pens Store in a refrigerator (2 °C-8 °C). Do not freeze. Do not put SoloStar next to the freezer compartment or a freezer pack. Keep the pre-filled pen in the outer carton in order to protect from light.
Apidra® SoloStar® solution for injection in a pre filled-pen INSTRUCTIONS FOR USE
HYPERGLYCAEMIA AND HYPOGLYCAEMIA Always carry some sugar (at least 20 grams) with you. Carry some information with you to show you are a person with diabetes. HYPERGLYCAEMIA (high blood sugar levels) If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin. Why does hyperglycaemia occur? Examples include:
SoloStar is a pre-filled pen for the injection of insulin. Your doctor has decided that SoloStar is appropriate for you based on your ability to handle SoloStar. Talk with your doctor, pharmacist or nurse about proper injection technique before using SoloStar. Read these instructions carefully before using your SoloStar. If you are not able to use SoloStar or follow all the instructions completely on your own, you must use SoloStar only if you have help from a person who is able to follow the instructions completely. Hold the pen as shown in this leaflet. To ensure that you read the dose correctly, hold the pen horizontally, with the needle on the left and the dosage selector to the right as shown in the illustrations below.
You can set doses from 1 to 80 units in steps of 1 unit. Each pen contains multiple doses.
Pen cap
Pen needle (not included)
Keep this leaflet for future reference. If you have any questions about SoloStar or about diabetes, ask your doctor, pharmacist or nurse or call the local Sanofi number on the front of this leaflet.
Pen body
Protective seal
Outer needle cap
Inner needle cap needle
Insulin reservoir
Injection button
Important information for use of SoloStar:
Step 3. Perform a safety test
Step 4. Select the dose
Step 6. Remove and discard the needle
Always perform the safety test before each injection. This ensures that you get an accurate dose by:
You can set the dose in steps of 1 unit, from a minimum of 1 unit to a maximum of 80 units. If you need a dose greater than 80 units, you should give it as two or more injections.
Always remove the needle after each injection and store SoloStar without a needle attached. This helps prevent:
B. Take off the outer needle cap and keep it to remove the used needle after injection. Take off the inner needle cap and discard it.
Step 1. Check the insulin A. Check the label on your SoloStar to make sure you have the correct insulin. The Apidra SoloStar is blue. It has a dark blue injection button with a raised ring on the top. B. Take off the pen cap. C. Check the appearance of your insulin. Apidra is a clear insulin. Do not use this SoloStar if the insulin is cloudy, coloured or has particles.
Step 2. Attach the needle
Keep
A. Check that the dose window shows "0" following the safety test. B. Select your required dose (in the example below, the selected dose is 30 units). If you turn past your dose, you can turn back down.
Discard
C. Hold the pen with the needle pointing upwards. D. Tap the insulin reservoir so that any air bubbles rise up towards the needle. E. Press the injection button all the way in. Check if insulin comes out of the needle tip.
Always use a new sterile needle for each injection. This helps prevent contamination, and potential needle blocks.
A. Put the outer needle cap back on the needle, and use it to unscrew the needle from the pen. To reduce the risk of accidental needle injury, never replace the inner needle cap.
Step 5. Inject the dose A. Use the injection method as instructed by your doctor, pharmacist or nurse. B. Insert the needle into the skin.
Storage instructions Please check the reverse (insulin) side of this leaflet for instructions on how to store SoloStar.
A. Remove the protective seal from a new needle. B. Line up the needle with the pen, and keep it straight as you attach it (screw or push on, depending on the needle type).
If your SoloStar is in cool storage, take it out 1 to 2 hours before you inject to allow it to warm up to room temperature. Cold insulin is more painful to inject. Discard your used SoloStar as required by your local authorities.
It is advisable to test your blood sugar immediately after taking glucose to check that you really have hypoglycaemia. C. Deliver the dose by pressing the injection button in all the way. The number in the dose window will return to "0" as you inject.
10 secs
You may have to perform the safety test several times before insulin is seen.
Legende / Legend Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:
296 x 628 mm 9 Pt 10 Pt 2/2
Druckbare Farben / Printing colours
Technische Information / Technical information
Pantone Black Pantone Blue 072 Pantone 186 Pantone Yellow
Kontur / Outline
Maintenance Protect your SoloStar from dust and dirt. You can clean the outside of your SoloStar by wiping it with a damp cloth. Do not soak, wash or lubricate the pen as this may damage it.
D. Keep the injection button pressed all the way in. Slowly count to 10 before you withdraw the needle from the skin. This ensures that the full dose will be delivered. The pen plunger moves with each dose. The plunger will reach the end of the cartridge when the total of 300 units of insulin has been used.
958664 028 1 26.03.2026 GS09
Dosage selector
Rubber seal
Schematic diagram of the pen
Warning symptoms of hypoglycaemia
SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date:
Dose window
Your SoloStar is designed to work accurately and safely. It should be handled with care. Avoid situations where SoloStar might be damaged. If you are concerned that your SoloStar may be damaged, use a new one.
What Apidra contains
Side effects where the frequency cannot be estimated from the available data
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Sanofi 410 Thames Valley Park Drive Reading Berkshire RG6 1PT UK Tel: 0800 035 2525 Email: [email protected]
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible
Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen is insulin glulisine.
Medicines with the same active substance, strength and form include: Apidra 100 Units/ml solution for injection in a cartridge, Apidra 100 Units/ml solution for injection in a vial. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of adults, adolescents and children 6 years or older, with diabetes mellitus, where treatment with insulin is required.
Posology
The potency of this preparation is stated in units. These units are exclusive to Apidra and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1).
Apidra should be used in regimens that include an intermediate or long acting insulin or basal insulin analogue and can be used with oral hypoglycaemic agents.
The dose of Apidra should be individually adjusted.
Special populations
Renal impairment
The pharmacokinetic properties of insulin glulisine are generally maintained in patients with renal impairment. However, insulin requirements may be reduced in the presence of renal impairment (see section 5.2).
Hepatic impairment
The pharmacokinetic properties of insulin glulisine have not been investigated in patients with decreased liver function. In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Elderly
Limited pharmacokinetic data are available in elderly patients with diabetes mellitus. Deterioration of renal function may lead to a decrease in insulin requirements.
Paediatric population
There is insufficient clinical information on the use of Apidra in children younger than the age of 6 years.
Method of administration
Apidra SoloStar 100 Units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used (see section 4.4).
Subcutaneous use
Apidra should be given by subcutaneous injection shortly (0‑15 min) before or soon after meals or by continuous subcutaneous pump infusion.
Apidra should be administered subcutaneously in the abdominal wall, thigh or deltoid or by continuous infusion in the abdominal wall. Injection sites and infusion sites within an injection area (abdomen, thigh or deltoid) should be rotated from one injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).
The rate of absorption, and consequently the onset and duration of action, may be affected by the injection site, exercise and other variables. Subcutaneous injection in the abdominal wall ensures a slightly faster absorption than other injection sites (see section 5.2).
Care should be taken to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use proper injection techniques.
Mixing with insulins
When administered as a subcutaneous injection, Apidra must not be mixed with other medicinal products except NPH human insulin.
For further details on handling, see section 6.6.
Before using SoloStar, the Instructions for use included in the Package leaflet must be read carefully (see section 6.6).
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypoglycaemia.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, neutral protamine Hagedorn [NPH], lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose. Concomitant oral antidiabetic treatment may need to be adjusted.
Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.
Hyperglycaemia
The use of inadequate doses or discontinuation of treatment, especially in insulin‑dependent diabetic, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.
Hypoglycaemia
The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed.
Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease, medicinal products such as beta blockers or after transfer from animal‑source insulin to human insulin.
Adjustment of dose may be also necessary if patients undertake increased physical activity or change their usual meal plan. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.
When compared with soluble human insulin, if hypoglycaemia occurs after an injection with rapid acting analogues, it may occur earlier.
Uncorrected hypoglycaemic or hyperglycaemic reactions can cause loss of consciousness, coma, or death.
Insulin requirements may be altered during illness or emotional disturbances.
Medication errors
Medication errors have been reported in which other insulins, particularly long-acting insulins, have been accidentally administered instead of insulin glulisine. Insulin label must always be checked before each injection to avoid medication errors between insulin glulisine and other insulins.
Excipients
This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially 'sodium‑free'.
Apidra contains metacresol, which may cause allergic reactions.
Combination of Apidra with pioglitazone
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Apidra is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema.
Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Handling of the SoloStar pre-filled pen
Apidra SoloStar 100 units/ml in pre‑filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used.
Before using SoloStar, the Instructions for use included in the Package leaflet must be read carefully. SoloStar has to be used as recommended in these Instructions for use (see section 6.6).
Studies on pharmacokinetic interactions have not been performed. Based on empirical knowledge from similar medicinal products, clinically relevant pharmacokinetic interactions are unlikely to occur.
A number of substances affect glucose metabolism and may require dose adjustment of insulin glulisine and particularly close monitoring.
Substances that may enhance the blood‑glucose‑lowering activity and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline, propoxyphene, salicylates and sulphonamide antibiotics.
Substances that may reduce the blood‑glucose‑lowering activity include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic medicinal products (e.g. olanzapine and clozapine).
Beta‑blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood‑glucose‑lowering activity of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.
In addition, under the influence of sympatholytic medicinal products such as beta‑blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.
Pregnancy
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of insulin glulisine in pregnant women.
Animal reproduction studies have not revealed any differences between insulin glulisine and human insulin regarding pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Caution should be exercised when prescribing to pregnant women. Careful monitoring of glucose control is essential.
It is essential for patients with pre‑existing or gestational diabetes to maintain good metabolic control throughout pregnancy. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly.
Breast-feeding
It is unknown whether insulin glulisine is excreted in human milk, but in general insulin does not pass into breast milk and is not absorbed after oral administration.
Breast‑feeding mothers may require adjustments in insulin dose and diet.
Fertility
Animal reproduction studies with insulin glulisine have not revealed any adverse effects on fertility.
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machines).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.
Summary of the safety profile
Hypoglycaemia, the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.
Tabulated list of adverse reactions
The following related adverse reactions from clinical studies were listed below by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
MedDRA Organ system classes
Very common
Common
Uncommon
Rare
Not known
Metabolism and nutrition disorders
Hypoglycaemia
Hyperglycaemia (potentially leading to Diabetic ketoacidosis(1))
Skin and subcutaneous tissue disorders
Injection site reactions
Local hypersensitivity reactions
Lipodystrophy
Cutaneous amyloidosis
General disorders and administration site conditions
Systemic hypersensitivity reactions
(1) Apidra 100 Units/ml solution for injection in a vial: Most of the cases were related to handling errors or pump system failure when Apidra was used with CSII.
Description of selected adverse reactions
• Metabolism and nutrition disorders
Symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation. Hypoglycaemia can become severe and may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.
• Skin and subcutaneous tissue disorders
Local hypersensitivity reactions (redness, swelling and itching at the injection site) may occur during treatment with insulin. These reactions are usually transitory and normally they disappear during continued treatment.
Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
• General disorders and administration site conditions
Systemic hypersensitivity reactions may include urticaria, chest tightness, dyspnoea, allergic dermatitis and pruritus. Severe cases of generalized allergy, including anaphylactic reaction, may be life‑threatening.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Hypoglycaemia may occur as a result of an excess of insulin activity relative to food intake and energy expenditure.
There are no specific data available concerning overdoses with insulin glulisine. However, hypoglycaemia may develop over sequential stages.
Management
Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carries some sugar lumps, sweets, biscuits or sugary fruit juice.
Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon or by glucose given intravenously by a healthcare professional. Glucose must also be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes.
Upon regaining consciousness, administration of oral carbohydrate is recommended for the patient in order to prevent relapse.
After treatment with glucagon, the patient should be monitored in a hospital in order to find the reason for this severe hypoglycaemia and prevent other similar episodes.
Ask anything about Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.